Abstract
Understanding basic processes of human neural stem cell (hNSC) biology and differentiation is crucial for the development of cell replacement therapies. Bcl-XL has been reported to enhance dopaminergic neuron generation from hNSCs and mouse embryonic stem cells. In this work, we wanted to study, at the cellular level, the effects that Bcl-XL may exert on cell death during differentiation of hNSCs, and also on cell fate decisions and differentiation. To this end, we have used both v-myc immortalized (hNS1 cell line) and non-immortalized neurosphere cultures of hNSCs. In culture, using different experimental settings, we have consistently found that Bcl-XL enhances neuron generation while precluding glia generation. These effects do not arise from a glia-to-neuron shift (changes in fate decisions taken by precursors) or by only cell death counteraction, but, rather, data point to Bcl-XL increasing proliferation of neuronal progenitors, and inhibiting the differentiation of glial precursors. In vivo, after transplantation into the aged rat striatum, Bcl-XL overexpressing hNS1 cells generated more neurons and less glia than the control ones, confirming the results obtained in vitro. These results indicate an action of Bcl-XL modulating hNSCs differentiation, and may be thus important for the future development of cell therapy strategies for the diseased mammalian brain.
Similar content being viewed by others
Main
The efficient generation of human neurons and glia from stem cells is the object of intense investigation, in the context of basic and preclinical cell replacement research.1, 2 Different means of genetic and epigenetic manipulations of stem cell cultures are being tested, aiming at enhancing their ability to generate the desired cell types.3, 4, 5, 6 In previous studies, we and others have demonstrated that Bcl-XL overexpression has a major impact on the generation of dopaminergic neurons from human neural stem cells (hNSCs) and mouse embryonic stem cells (mES).7, 8 Also, recent data from conditional Bcl-XL mutant mice add support to these observations.9, 10 In the present study, we are extending these observations and analyzing in detail the effects of Bcl-XL on hNSCs differentiation, focusing on precursor cell fate choices, cell death, and precursor proliferation.
Bcl-XL is the most potent antiapoptotic protein among Bcl-2 family members, both in vitro and in vivo.11, 12, 13, 14 More specifically, Bcl-XL is essential for neuronal survival during brain development and in the adult central nervous system (CNS) (knockout mice and gene-expression studies15, 16). In addition to its antiapoptotic role, recent studies have described new roles of Bcl-XL in cell physiology – effects on Ca2+ homeostasis and gene expression17 and synaptic transmission regulation18 – under not necessarily apoptotic conditions. Several other studies have also described the role of Bcl-XL in the control of cell cycle,19, 20 a process well known to be tightly linked to progression of precursor cells toward neuronal and glia differentiation.21, 22
In this work, we aimed to elucidate the role of Bcl-XL in the generation of neurons and glia from both v-myc immortalized and non-immortalized hNSCs.
In vivo, numerous studies have shown that hNSCs can integrate, migrate, and differentiate when transplanted into the developing or young adult rodent and primate brain.1, 2, 23, 24, 25 Since neurodegenerative diseases are in many cases late-onset diseases, we found therefore of interest to study the in vivo properties of control or Bcl-XL overexpressing hNS1 cells after transplantation into the aged rat brain. Consistent with the in vitro data, we have also observed an increased neuron production and a diminished glia yield from Bcl-XL–overexpressing hNS1 cell transplants.
Results
Effects of Bcl-XL on hNSCs differentiation
When studying the yield of β-III-tubulin+ cells and GFAP+ cells by control or stable Bcl-XL hNS1 cells after 12 days of differentiation, we observed some interesting effects: (i) an increase in the percentage of neurons (8.08±0.55% in control versus 21.87±0.87% for Bcl-XL cells). (ii) A profound decrease in the percentage of glia (61.13±1.68% in control versus 12.88±0.85% in Bcl-XL cells) (Figure 1a, b, d). (iii) The total number of cells per field was significantly increased in Bcl-XL cultures (92±7.8 in control, versus 148±13 for Bcl-XL cells) (Figure 1c, see also Figure 5c). And (iv) the percentage of differentiated cells (glia and neurons together) was decreased in the Bcl-XL cultures (Figure 1e). As shown in Figure 1f, Bcl-XL protein levels were increased in Bcl-XL cells as compared to the controls, both under proliferation and differentiation conditions.
The data just described were obtained from a stable clone of hNSCs overexpressing Bcl-XL for prolonged periods of time. To study Bcl-XL effects in a shorter time scale, we infected control hNS1 cells with retroviral vectors coding for Bcl-XL and green fluorescent protein (GFP), or only GFP (empty vector used as a control), on day 1 of differentiation, and the cells were let to differentiate until day 12. The efficiency of infection of both viral vector preparations was equivalent, as determined on day 3 post-infection (approximately 12–13% of GFP+ cells; Supplementary Figure S1). Phenotypic analysis of GFP+ cells after differentiation revealed that 70.3±1.4% of them in the Bcl-XL group were β-III-tubulin+, while only 20.5±1.8% were β-III-tubulin+ in the control group (P<0.01; Student's t-test; n=4) (Figure 2a and b). On the contrary, the analysis of glial cell generation showed a significant reduction of GFP+–GFAP+ cells in Bcl-XL transduced cells (14.4±1.3%) as compared with the empty vector group (34.4±0.9%) (P<0.05; Student's t-test; n=4) (Figure 2c and d).
To rule out the possibility that the observed Bcl-XL effects could be related to an interaction of Bcl-XL with v-myc in the cellular context, we studied the effects of Bcl-XL on the differentiation of non-immortalized forebrain hNSCs. Cells were infected with the same vectors as described above, and their differentiation was studied. Efficiency of infection was in the range of 9–12%, similar to that seen in immortalized cells. As shown in Figure 2e–g, Bcl-XL overexpression resulted in a higher yield of neurons, and a parallel decrease in the number of GFAP+ cells generated.
Therefore, the Bcl-XL effects described so far are not related to a prolonged exposure of the cells to high Bcl-XL levels, neither to v-myc nor the nature of the hNSCs (either cell lines or non-immortalized cultures).
Differentiation ‘time course’ of control or stable Bcl-XL overexpressing hNS1 cells
To obtain further insights into Bcl-XL effects, we studied the time course of differentiation of both control and Bcl-XL hNS1 cells. Neurons (β-III-tubulin+ cells) were generated at the same pace by both cell types. The neuronal yield was higher in Bcl-XL cultures at every time-point studied (Figure 3a and c). Glial cells (GFAP+) appeared on the same days for both types of cultures, but their numbers were significantly less in Bcl-XL cultures than in control cells (Figure 3d and f). Normalized data for neurons (Figure 3b) and glia (Figure 3e) indicated that GFAP generation might be delayed in Bcl-XL cells. To rule out this possibility, we conducted an additional series of experiments aimed to reach day 21 of differentiation (Figure 3c and f). As a result, we got the same information as shown before in panels a and d, even when prolonging the time of differentiation. To strengthen the data obtained above, we performed the same time course and assay cell cultures for microtubule-associated protein 2 (Map-2) and synapsin-I markers, which both show the same pattern as β-III-tubulin+ cells, confirming our previous conclusions (Figure 3g–i). Regarding glia cells, we quantified the vimentin+ cells and observed that their number decreased in the same amount for Bcl-XL and control cultures (Figure 3j). Moreover, the vimentin cells start to express GFAP along the time of differentiation; quantification of the vimentin+-GFAP+ cells appearing in the culture (Figure 3k and l) showed that this number was greatly decreased in Bcl-XL cultures, as compared to the controls. These data suggest that the transition between vimentin+ cells to mature glia (GFAP+) is prevented by Bcl-XL in hNS1 cultures.
Cell death during differentiation
To ascertain the role of cell death during differentiation of hNS1 cells, we studied several cell death-related parameters (Figure 4): (i) number of alive/dead–dying cells (calcein/PI staining of alive cultures, Figure 4a); (ii) percentage of cells with fragmented DNA determined by flow cytometry (cells fitting in the sub-G0/G1 region of the nuclear DNA distribution) which indicates programmed cell death, Figure 4b); (iii) number of cells showing a condensed/fragmented nucleus (Hoechst staining microscopy, Figure 4c); (iv) the percentage of Annexin-V+ cells (cells undergoing a programmed cell death process, Figure 4d). Data obtained with all four techniques illustrate that cell death is not a major event taking place in our system during the differentiation ‘time course’. The proportion of alive and dead–dying cells did not substantially change with time.
To obtain further insights, we assessed the undergoing apoptosis for every phenotype along the differentiation period. We quantified the number of cells co-labeled for cleaved caspase-3 and β-III-tubulin, GFAP and nestin, respectively (Figure 4e–g). As shown in Figure 4e and f, Bcl-XL protects the neurons and neural cells against cell death as compared to controls, but at very low rate (less than 2%). Moreover, we have not found any double caspase-3+-GFAP+ cells.
Bcl-XL effects on cell proliferation during the differentiation period
To investigate Bcl-XL effects on cell proliferation, we first performed a pulse and chase experiment (Figure 5a). Using this experimental design, we detected a trend for an increase in the number of cells incorporating bromodeoxyuridine (BrdU) in Bcl-XL cultures as compared with control hNS1 cells on days 3–5 of differentiation (Figure 5b and e). Consistent with this, the total number of cells in the Bcl-XL cultures increased from day 5 onwards in comparison to control cultures (Figure 5c).
To have a second confirmation of the presence of proliferating cells in the cultures, we stained parallel samples for Ki-67 (a marker expressed during most of the cell cycle26) and, as expected, we found more cells still in cycle in Bcl-XL cultures, from day 5 onwards (Figure 5d and e).
Bcl-XL modulates the production of neurons and glia from their precursors
Since cell death or differences on the time set of neurons and glia production were not the decisive cause of different yielding observed; and because existence of a trend on an increased proliferation in Bcl-XL cultures detailed above, we investigated what precursors of both cell types render on after the differentiation. With this aim, we pulsed the cells on different days and allowed them to differentiate until day 12 (Figure 6a). As Figure 6b and c show, there are higher number of cells that, when pulsed in the first days of differentiation, produce more neurons, detected as double β-III-tubulin+–BrdU+ in Bcl-XL cultures. However, the opposite happens for GFAP+ cells (Figure 6c and d), there are less GFAP+–BrdU+ in Bcl-XL overexpressing cells. We concluded that Bcl-XL is increasing the number of precursor proliferation that render on β-III-tubulin cells on day 12 or that these precursors differentiate more in Bcl-XL cultures, it means an induction of the neuron phenotype. In the case of GFAP cells, it is a matter of decreased precursor proliferation or a hampered differentiation.
Bcl-XL promotes the proliferation of neural (Nestin+) and neuronal precursor (β-III-tubulin+) cells at early times during differentiation of hNS1 cells but not of vimentin+ cells
In order to discern between the two possibilities raised on the above experiment, we analyzed the immediate phenotype of the proliferating cells during the differentiation period and studied Bcl-XL effects on them. We pulsed differentiating cell cultures for 24 h with BrdU (Figure 7a), and the cells were subsequently processed for immunocytochemistry (ICC) (Figure 7b).
Quantification of BrdU- or Nestin+ cells revealed a similar temporal profile for both markers over the studied time course (Figure 7c and d). Bcl-XL increased the number of BrdU+ and Nestin+ cells during the whole of the differentiation period, as compared to the controls. Quantification of the number of double BrdU+–Nestin+ cells (Figure 7e) indicated that most of the BrdU+ cells were Nestin+, while approximately one half of the Nestin+ cells incorporated BrdU. This was expected, considering that the hNS1 cells have a cell-cycle length of 40 h27, 28 and that they were exposed to BrdU for 24 h only. Bcl-XL did not influence these figures substantially, but at days 3–4 of differentiation, a two-fold increase in the number of Nestin+ cells also incorporating BrdU was detected. Overall, Ki-67, Nestin, and BrdU data (Figures 5 and 7b–e) suggest that Bcl-XL is promoting cell proliferation.
Next, we analyzed the extent of GFAP or β-III-tubulin precursor cells that were proliferating at the time points analyzed, and if Bcl-XL had any effect on their proliferation.
As shown in Figure 7f, the percentage of total cells staining for GFAP and BrdU was almost negligible during the time course (below 1% of the total number of cells). Furthermore, it did not significantly change with time, or after Bcl-XL overexpression. Owing to this result, we checked the percentage of vimentin+–BrdU+ cells and observed that Bcl-XL overexpression does not have any effect on vimentin+ cell proliferation (Figure 7h).
In the case of β-III-tubulin+ cells (Figure 7g), Bcl-XL cultures showed an increase of β-III-tubulin+–BrdU+ cells, particularly during the early days of the time course, while control hNS1 cells did only show a very low percentage of these cells being positive for BrdU and β-III-tubulin (around 1% in control cultures). All of these data indicated an increase of proliferating Nestin+ cells, neuron progenitor proliferation and non-influence on glia lineage proliferation. Moreover, the proportion of β-III-tubulin+–BrdU+ cells to total β-III-tubulin+ pool is the same for Bcl-XL cultures as control one, while the proportion of β-III-tubulin+-BrdU+ cells to the total mitotic (BrdU+) cells is higher in Bcl-XL overexpressing cells, corroborating the data explained above (Supplementary Figure S2).
Bcl-XL effects on hNS1 cell grafts into the aged rat striatum
Four weeks after intrastriatal cell implantation, three out of five rats receiving control cells, or four out of five animals implanted with Bcl-XL hNS1 cells had surviving grafts, as determined by the presence of human nuclei (hNuc) stained cells (Figure 8a). hNuc+ cells were mainly located at the striatal implantation site and no signs of tumor formation were observed in any transplanted animals, according to previous studies.8, 29, 30 Morphometric assessment of graft properties indicated that graft volume was larger for Bcl-XL cell grafts as compared to control cell grafts. (i) Antero-posterior extension of the grafts was 0.53±0.13 mm in control grafts and 1.09±0.11 mm in Bcl-XL transplants (P<0.05; Student's t-test). (ii) Total graft volume increased from 0.032±0.006 mm3 in control cell grafts to 0.34±0.05 mm3 in Bcl-XL grafts (P<0.05; Student's t-test). In agreement with previous results obtained in grafting studies in neonatal or young adult rats,8, 29, 30 control hNS1 cells generated very few doublecortin (Dcx+) or human neuron-specific enolase (hNSE+) neurons when grafted into the striatum of aged rats, as expected from a non-neurogenic area, and aged tissue environment, receiving a NSCs graft. In contrast, Bcl-XL cell transplants were richer in Dcx+ and hNSE+ cells, as obvious from graft examination. Quantification of cell numbers was precluded by the high cell density of the grafted cells. Grafts of control hNS1 cells showed a dense (intense) GFAP immunoreactivity, sending an extensive network of processes to the host brain. GFAP immunoreactivity was also present in Bcl-XL grafts, but this was less intense and more confined to the transplant site.
Phenotypical identities of the grafted cells were analyzed by double labeling for hNuc+ and Nestin+ (undifferentiated precursors), Dcx+ (neuroblasts) or GFAP+ (glia), under confocal z axis serial images (Figure 8b). No hNuc+–Nestin+ or hNuc+–Dcx+ cells were detected in the striatal grafts of control hNS1 cells, in contrast with the abundance of double-labeled cells found for both antigens in the Bcl-XL grafts (22.13±2.6% of hNuc+–Dcx+ and 26.1±1.3% of hNuc+–Nestin+ cells, respectively; mean±S.E.M.). Conversely, many hNuc+–GFAP+ cells were found in control grafts (96.2±0.85%) whereas in the Bcl-XL grafts their number was markedly reduced (24.6±4.3%) (P<0.01; Student's t-test).
Discussion
Understanding how human stem cells can generate differentiated neural cell types is crucial for basic developmental studies and for the development of future cell therapies for nervous system diseases.1, 2 Our data indicate that transient Bcl-XL overexpression instructively direct the fate of both immortalized and naive hNSCs towards neurons while decreasing glia generation. These effects were even more prominent in stable Bcl-XL-overexpressing immortalized hNSCs, and they could be related to the following.
Survival
The antiapoptotic role of Bcl-XL has been well established in previous studies dealing with the differentiation of neural progenitors, and neural cells, in general.9, 13, 14 Bcl-XL is required for neuronal survival during brain development and in the postnatal period.16 Indeed, extensive apoptotic cell death was observed in the developing brain of Bcl-XL-deficient mice embryos.15 Bcl-XL has also been recently reported to play a crucial role in neuronal development/survival in conditional null mice specific for catecholaminergic cells.9 Our data indicated that total cell death is not playing a major role in our differentiation system neither in absolute terms, nor with time. However, and according to other studies, a decrease in apoptotic (caspase-3+) cell death of Nestin+ and β-III-tubulin+ cells was observed in stable Bcl-XL overexpressing cells as compared to control hNS1 cells along the differentiation period. This antiapoptotic effect, even not irrelevant, seems to be too small to explain per se the high increase of in vitro generated neurons and the dramatic reduction in the yield of glial cells in Bcl-XL cultures, but we do not discard a minor protective effect in neural and neuronal cells.
Differentiation
When the β-III-tubulin and GFAP generation time courses are studied in detail, we conclude that Bcl-XL effects were due to the magnitude, not the rate, of neurons and glia generation. This observation was reinforced by the study of more mature neuronal markers (Map-2 and synapsin-I), which showed similar profiles of expression over time. Turning to glia, we also performed a time course to study vimentin cells, which decreased at the same pace for both cell types (control or Bcl-XL).
Similar results, in terms of neuron/glia generation were observed when cells were run until day 21 of differentiation, therefore discarding a possible ‘delay of differentiation’.
Progenitor proliferation during hNS1 cell differentiation
BrdU incorporation data showed a trend for an increase in the number of BrdU+ cells in Bcl-XL cells as compared to control cultures on day 3 of differentiation. The percentages of Ki-67+ cells, and total cell numbers were also significantly increased in Bcl-XL cultures after day 5 of differentiation. These results strongly indicate that Bcl-XL is modulating – cell proliferation in our system, in agreement with other reports.19, 20
The analysis of the proliferation of neural precursor cells (Nestin+–BrdU+), glia progenitor/precursor cells (GFAP+–BrdU+ and vimentin+–BrdU+), and neuronal progenitors (β-III-tubulin+–BrdU+) showed: Firstly, the quantification of BrdU+ or Nestin+ cells confirmed the expected parallel temporal profile for both markers and Bcl-XL increased the numbers of stained cells during the whole of the differentiation period. These findings are consistent with results from studies using mES cells,7 and bax–bak-deficient mice which displayed an increased pool of progenitor cells in the sub-ventricular zone.31 Second, quantification of double BrdU+–Nestin+ cells indicated that most of the proliferating cells (BrdU+) were Nestin+, while approximately one half of the Nestin+ cells incorporated BrdU. Moreover, Bcl-XL overexpression increased twofold the number BrdU+–Nestin+ cells pulsed during days 3–4. These data suggest that Bcl-XL is promoting the proliferation of undifferentiated (Nestin+) cells (see Figure 9).
Third, BrdU incorporation into GFAP+ precursor cells was negligible, and Bcl-XL had no effect on this parameter. We performed the same BrdU marking strategy with vimentin cells and observed that they incorporated BrdU at the same rate even when Bcl-XL was overexpressed, allowing us to state that Bcl-XL does not affect the proliferation of immature glia. Finally, the number of neuronal precursor cells incorporating BrdU (β-III-tubulin+–BrdU+ cells) was increased in Bcl-XL cultures. Overall, we concluded that Bcl-XL promotes the proliferation of neural precursors and neuronal progenitors, that the last phenomenon may be responsible for the increased number of post-mitotic neurons, and that the diminished production of glia is due to a block in differentiation of their precursors.
Regarding the mechanism explaining the increase in neuron generation observed here after Bcl-XL overexpression, it is important to highlight that cell proliferation has been shown to be a prerequisite for increased neuron generation in other studies.22 Present results could be reminiscent to those observed after valproate (an inhibitor of histone deacetylase) treatment of human fetal forebrain stem cells.5 Similarly, Wnts have been recently found to enhance neurogenesis from hippocampus-derived precursors, through the stimulation of neuroblast proliferation.6 Also, pro-neural transcription factors of the helix–loop–helix family, such as neurogenin and Mash132, 33 have been reported to enhance neuron generation through an increased proliferation of their progenitors. In fact, Mash1 deletion mutant mice show decreased cell proliferation, and reduced brain size and neuronal generation/differentiation in the ventral forebrain.34 Moreover, the same transcription factors have been implicated in the inhibition of generation of glial cells. Future molecular and genetic studies will be needed to elucidate the molecular mechanisms responsible for the Bcl-XL effects described here.
In vivo, after transplantation into the aged rat striatum (to mimic the situation of a late-onset disease, with a preclinical orientation), grafts of Bcl-XL overexpressing hNS1 cells survived better, and contained more neuronal cells and less glial cells than control hNS1 cell grafts. Similarly, mouse ES cells overexpressing Bcl-XL showed a better reinnervation of the striatum of 6-OH-DA rats.7 In the present work, it is important to note that Bcl-XL did enhance hNSCs survival and neuronal differentiation, when implanted in a non-neurogenic site and, furthermore, impoverished, due to aging, for the supply of trophic factors such as brain-derived neurotrophic factor.35 Therefore, Bcl-XL seems to be able to override some of the tissue-imposed limitations for in vivo neuron generation by hNSCs.
In conclusion, in the context of hNSCs research, amounting data indicate that Bcl-XL plays a major role in modulating the generation of neurons from both rodent- and human-derived stem cells,7, 8, 9, 10 and present work. Here, we contribute data indicating a more general role of Bcl-XL, controlling the balance between the generation of neurons and glia from differentiating immortalized and non-immortalized hNSCs. In future work, it will be important to analyze the mechanisms of action of Bcl-XL at the molecular level, and also the interaction of Bcl-XL overexpressing cells with the surrounding environment after transplantation.
Materials and Methods
Cell culture
Cell lines of hNSCs. In this study, we have used control and Bcl-XL overexpressing hNSCs derived from the hNS1 cell line (whose properties have been extensively described elsewhere).8, 27, 28, 30, 37 This is a v-myc immortalized, non-transformed, human fetal forebrain-derived, multipotent, and clonal cell line of neural stem cells. hNS1 cell culture conditions are based on a chemically defined HSC-medium supplemented with 20 ng/ml of each epidermal growth factor (EGF) and basic fibroblast growth factor (FGF2).27 Cells were proliferated at 5% CO2 and normal atmospheric oxygen levels (resulting in 20% O2). Cultures were differentiated on poly-L-lysine (10–50 μg/ml; Sigma) coated plastic or glass coverslips, by withdrawal of growth factors (EGF and FGF2) and addition of 0.5% heat-inactivated fetal bovine serum (FBS), for 12 days or the indicated times, at 5% O2 and 5% CO2 in a dual control O2–CO2 incubator (Forma).8
Non-immortalized forebrain hNSCs
Tissue was obtained from an aborted human fetus of 10 weeks gestational age (Lund University Hospital/Wallenberg Neuroscience Center; Dr Bengt Juliusson; Lund, Sweden). The tissue was donated for research after informed consent, and following EU directives, NECTAR recommendations, and Spanish law RD 42/1988. All procedures did follow Society for Neuroscience recommendations, and were also approved by the Bioethics of Research Committee of the University Autónoma of Madrid (Spain). Tissue pieces were digested to generate adherent primary cultures (2 × 105 cells per well of a 24-well plate), passed two times, and used for experimentation. Cells (secondary cultures) were grown as adherent cultures in the standard medium for hNSCs (i.e., under the influence of EGF and bFGF, 20 ng/ml each).
BrdU incorporation
To study cell proliferation during differentiation experiments, and Bcl-XL effects on it, cultures were pulsed with BrdU (Sigma) under three different experimental designs.
Experiment 1: general cell proliferation rate. BrdU (10 μM) was applied for 2 h at days 0, 1, 3, 5, 7, 9, or 12 of the differentiation time course, and the cells were immediately fixed after the BrdU pulse for ICC.
Experiment 2: labeling of proliferating precursors that, after completion of the 12-day differentiation period, yielded β-III-tubulin+ or GFAP+cells (birth dating). BrdU (1 μM) pulse was applied during 24 h at differentiation days 1, 3, 6, or 8 and the cells were let to differentiate until day 12 being subsequently fixed.
Experiment 3: proliferation of Nestin, β-III-tubulin, GFAP or vimentin precursors: BrdU (1 μM) was applied as in Experiment 2 but the cells were fixed immediately afterwards.
Bcl-XL overexpression in hNSCs
The generation of stable Bcl-XL overexpressing hNSCs (hNS1 subclone 5) was previously described.8 Since continued Bcl-XL expression in selected clones could result in changes in the cell's biology not directly linked to Bcl-XL actions, we have also studied Bcl-XL effects at a shorter time scale (days after transfection) (compare experiments shown in Figures 2 and 3). To this end, we infected control hNS1 cells with murine leukemia virus-derived, vesicular stomatitis virus glycoprotein pseudotyped retroviral vector stocks (generated in HEK 293 cells using the pVP-pack Stratagene system). Vectors had the following structure. Control vector: LTR-(empty)-IRES-RhGFP-LTR. Bcl-XLvector: LTR-(Bcl-XL)-IRES-RhGFP-LTR. (Rh-GFP stands for humanized Renilla raniformis-GFP.) Rh-GFP was subcloned into the retroviral backbone from the pFB-RhGFP plasmid. Titers were determined on HEK293 cells, and retroviral particles were used to infect hNS1 cells at a multiplicity of infection of one particle per cell. Cells were plated (day 0) in proliferation medium and differentiation was started at day 1. On day 2, cells were infected with retroviral stocks (prepared in Dulbecco's modified Eagle's medium/F-12 containing 5% FBS) for 4 h. After that, the regular differentiation medium was replaced, and the cells were let to differentiate until day 12.
For infection of non-immortalized forebrain hNSCs, cells were seeded at 2 × 105 cells/cm2 (day 0) and infected in the same way as for hNS1, at day 1. On day 2, differentiation was started, by adding regular differentiation medium.
ICC and immunoblotting (WB)
At the specified time points, the cultures were rinsed with PBS and fixed for 10 min in freshly prepared 4% PFA/PHEM/4% sucrose.38 Cultures were blocked for 1 h in 10% normal horse serum, 0.25% Triton X-100 in PBS and incubated overnight at 4°C with mouse monoclonal antibodies against β-III-tubulin (1 : 1000; Sigma), GFAP (1 : 1000; Sigma), Nestin (1 : 500; Transduction Laboratories), vimentin (1 : 1000, Santa Cruz) and Map-2 (1 : 1000; Sigma) or monoclonal rat antibodies against BrdU (1 : 500; Abcam, UK) or rabbit antiserum against Ki-67 (1 : 3000; Lab Vision, UK), cleaved caspase-3 (1 : 100; Cell Signaling) synapsin-I (1 : 500; Chemicon) and GFAP (1 : 2000; DakoCytomation, Denmark).
On the next day, the cultures were incubated with biotinylated horse anti-mouse antibodies (1 : 200; Vector Laboratories) followed by streptavidin-CY3 (1 : 300, Jackson Immunoresearch) or FITC-conjugated antibodies (goat anti-rat, or -goat anti-rabbit, 1 : 200; Jackson Immunoresearch) or CY3-conjugated (goat anti-mouse; 1 : 300, Jackson Immunoresearch) or CY5-conjugated antibodies (donkey anti-rabbit; 1 : 300, Jackson Immunoresearch. For non-fluorescent ICC, samples were developed using the Vector ABC kit followed by diaminobenzidine (DAB) development. Cell nuclei were counterstained with Hoechst 33258 (Molecular Probes, Eugene, OR, USA) at 0.2 μg/ml in PBS. For BrdU ICC, before incubation with the first antibody, fixed cultures were treated with 2 M HCl at 37°C for 30 min, followed by three rinses in 0.1 M borate buffer (pH 8.9). For double ICC for BrdU and other antigens, BrdU processing and staining was performed as a second ICC round. Cell nuclei staining in BrdU ICCs was performed using propidium iodide (PI; Sigma) (1 μg/ml in PBS) at the end of the staining process. For western analysis, 30 μg of protein from dividing or differentiated cultures were assayed. Samples were electrophoresed and transferred to nitrocellulose membranes overnight. Primary antibodies were mAb anti-β-actin (1 : 5000; Sigma) and rabbit polyclonal anti-Bcl-XL (1 : 1000; Transduction Laboratories). The blots were developed using peroxidase-conjugated horse anti-mouse (horse anti-mouse peroxidase (HAMPO), 1 : 5000; Vector Laboratories) or goat anti-rabbit antibodies (goat anti-rabbit peroxidase (GARPO), 1 : 10 000; Nordic Immune) and developed using the ECL system (Amersham Biosciences, Arlington Heights, IL, USA).
Cell death
To study cell death parameters during differentiation of hNS1 and Bcl-XL overexpressing cells, we performed the following experiments combining different techniques:
(a) The number of alive and dying–dead cells was quantified in alive cultures stained with calcein-AM/PI (1 μM calcein-AM (Molecular Probes) and 4 μM PI (Sigma)). Cells were stained for 15 min at 37°C and photographed, for offline quantification. Green cells are alive cells, while red-stained nuclei identify dead or dying cells.
(b) Analysis of Annexin V+ cells, and nuclear morphology: phosphatidylserine exposure on the outer leaflet of the plasma membrane39 was detected using the fluorescent dye Annexin V-CY5 (Annexin-V-CY5 detection Kit (Abcam) according to the manufacturer's instructions. In brief, at specified time points culture medium was replaced by Annexin V binding buffer, then 1 μl of Annexin V-CY5 antibody was added and the cells were incubated in this solution for 5 min at room temperature. Nuclei were counterstained with Hoechst 33258 (Molecular Probes, 0.2 μg/ml in PBS, for 10 min). Dying–dead cells were identified by showing a condensed or fragmented nucleus.
(c) Determination of the sub-G0/G1 cell population by flow cytometry:40 cells were trypsinized, washed in PBS, fixed with 70% ethanol at −20°C, and stored at −20°C until all the time points were collected. At the time of analysis, cells were incubated in the staining solution for 30 min at 37°C (PBS containing 0.1% of sodium citrate, 0.3% of NP-40, 0.02 mg/ml of RNase, and 0.05 mg/ml of PI (Sigma)). DNA content was determined using a fluorescence-activated cell sorter, FACS Calibur flow cytometer (BD Bioscience). A total of 10 000 events were acquired per sample and data were analyzed by CellQuest Software (BD Bioscience).
Image and data analyses on cell cultures
Analyses and photography of fluorescent- or DAB-immunostained cultures were carried out in an inverted Zeiss (Oberkochen, Germany) Axiovert 135 or Leica (Nussloch, Germany) DM IRB (equipped with a digital camera Leica DC100) microscopes. In some experiments, digitized images were captured using Leica IM500 Software. Image analyses were performed using NIH Image Software. Statistical tests were run using Prophet Software (NIH). Results are shown as the average±S.E.M. of data from four to five experiments, unless stated otherwise.
In vivo transplantation
Aged female Wistar rats (23 months old), housed and treated according to the European Community guidelines (86/609/EEC) were anesthetized with a mix of Ketamine and Dontor, and grafted onto the right striatum with cellular suspensions of proliferating control hNS1 cells (n=5) or Bcl-XL–hNS1 cells (n=5), at the following coordinates (in mm, tooth bar set at −2.3): antero-posterior (AP)=+1; medio-lateral (ML)=−3; dorso-ventral (DV) (from dura)=−4.5. A total of 400 000 cells were implanted as a single deposit (cell density of 150–200 000 cells/μl). The animals were immune suppressed with cyclosporine A (Neoral; Novartis) at 100 μg/ml in drinking water, starting 48 h before grafting. Four weeks after grafting, rats were intracardially perfused with freshly prepared, buffered 4% paraformaldehyde. Brains were post-fixed for 12 h, dehydrated in 30% sucrose, and sectioned (30 μm, freezing microtome) for free-floating immunohistochemistry analyses. Serial sections were processed for monoclonal anti-hNuc (MAB 1281; 1 : 500; Chemicon) to detect all grafted and surviving human cells. Migrating neuroblasts and immature neurons were detected using anti-Dcx antibodies (C-18; 1 : 1000; Santa Cruz Biotechnology), and human neurons were specifically stained using an anti-human neuron-specific enolase antibody (MAB324; 1 : 2000; Chemicon). Undifferentiated cells were detected using polyclonal anti-Nestin antibody (1 : 1000; Abcam). Astroglial cells were stained with a polyclonal antibody anti-GFAP (1 : 2000; Dako, Denmark). For the unambiguous detection of GFAP, Nestin, or Dcx in human cells, double IHC was performed combining these antibodies with those for hNuc. Secondary antibodies were biotinylated horse anti-mouse (1 : 200; BA2001; Vector Laboratories), followed by ABC (Vector Laboratories) and Ni–DAB reaction. For immunofluorescence (IF) secondary antibodies were conjugated to Texas Red (horse anti-mouse; 1 : 100; Vector Laboratories), Alexa 488 (goat anti-rabbit; 1 : 400; Molecular Probes), or FITC (donkey anti-goat; 1 : 200; Jackson Immunoresearch).
Single IF or DAB sections were analyzed on a Leica DM IRB inverted fluorescence microscope. For double IF analyses, sections were analyzed on a Microradiance Confocal microscope (Bio-Rad, Hercules, CA, USA). To determine the phenotype of transplanted cells, hNuc+ cells double immunostained for Nestin, Dcx, or GFAP, were analyzed in confocal z axis serial images (at 63 × magnification). A total of 3–4 sections per animal (n=3 in control group and n=4 in Bcl-XL group) and between 300 and 500 cells per section were analyzed. For each hNuc+ cell, the complete cell nucleus was scanned through the z axis, and only cells with a well circumscribed, immunopositive cell body or nucleus were considered positive for a particular phenotype. Orthogonal projections and volume quantifications were done from low magnifications (25 × , 40 ×) z images (0.5–1 μm thickness) using Metamorph software (Universal Imaging Corporation, West Chester, PA, USA).
Abbreviations
- BrdU:
-
bromodeoxyuridine
- CNS:
-
central nervous system
- DAB:
-
diaminobenzidine
- Dcx:
-
doublecortin
- EGF:
-
epidermal growth factor
- FBS:
-
fetal bovine serum
- FGF2:
-
basic fibroblast growth factor
- GARPO:
-
goat anti rabbit peroxidase
- GFAP:
-
glial fibrilary acid protein
- GFP:
-
green fluorescent protein
- HAMPO:
-
horse anti mouse peroxidase
- hNSE:
-
human neuron-specific enolase
- hNSC:
-
human neural stem cells
- hNuc:
-
human nuclei
- ICC:
-
immunocytochemistry
- Map-2:
-
microtubule-associated protein 2
- mES:
-
mouse embryonic stem cells
- PI:
-
propidium iodide
References
Lindvall O, Kokaia Z, Martinez-Serrano A . Stem cell therapy for human neurodegenerative disorders – how to make it work. Nat Med 2004; 10: S42–S50.
Goldman S . Stem and progenitor cell-based therapy of the human central nervous system. Nat Biotechnol 2005; 23: 862–871.
Suzuki M, Wright LS, Marwah P, Lardy HA, Svendsen CN . Mitotic and neurogenic effects of dehydroepiandrosterone (DHEA) on human neural stem cell cultures derived from the fetal cortex. Proc Natl Acad Sci USA 2004; 101: 3202–3207.
Hsieh J, Nakashima K, Kuwabara T, Mejia E, Gage FH . Histone deacetylase inhibition-mediated neuronal differentiation of multipotent adult neural progenitor cells. Proc Natl Acad Sci USA 2004; 101: 16659–16664.
Laeng P, Pitts RL, Lemire AL, Drabik CE, Weiner A, Tang H et al. The mood stabilizer valproic acid stimulates GABA neurogenesis from rat forebrain stem cells. J Neurochem 2004; 91: 238–251.
Lie DC, Colamarino SA, Song HJ, Desire L, Mira H, Consiglio A et al. Wnt signaling regulates adult hippocampal neurogenesis. Nature 2005; 437: 1370–1375.
Shim JW, Koh HC, Chang MY, Roh E, Choi CY, Oh YJ et al. Enhanced in vitro midbrain dopamine neuron differentiation, dopaminergic function, neurite outgrowth, and 1-methyl-4-phenylpyridium resistance in mouse embryonic stem cells overexpressing Bcl-XL . J Neurosci 2004; 24: 843–852.
Liste I, Garcia-Garcia E, Martinez-Serrano A . The generation of dopaminergic neurons by human neural stem cells is enhanced by Bcl-XL, both in vitro and in vivo. J Neurosci 2004; 24: 10786–10795.
Savitt JM, Jang SS, Mu W, Dawson VL, Dawson TM . Bcl-x is required for proper development of the mouse substantia nigra. J Neurosci 2005; 25: 6721–6728.
Chang MY, Sun W, Ochiai W, Nakashima K, Kim SY, Park CH et al. Bcl-XL /Bax proteins direct the fate of embryonic cortical precursor cells. Mol Cell Biol 2007; 27: 4293–4305.
Gonzalez-Garcia M, Garcia I, Ding L, O'Shea S, Boise LH, Thompson CB et al. Bcl-x is expressed in embryonic and postnatal neural tissues and functions to prevent neuronal cell death. Proc Natl Acad Sci USA 1995; 92: 4304–4308.
Krajewska M, Mai JK, Zapata JM, Ashwell KW, Schendel SL, Reed JC et al. Dynamics of expression of apoptosis-regulatory proteins Bid, Bcl-2, Bcl-X, Bax and Bak during development of murine nervous system. Cell Death Differ 2002; 9: 145–157.
Benn SC, Woolf CJ . Adult neuron survival strategies: slamming on the brakes. Nat Rev Neurosci 2004; 5: 686–700.
Jordan J, Galindo MF, Tornero D, Gonzalez-Garcia C, Cena V . Bcl-x L blocks mitochondrial multiple conductance channel activation and inhibits 6-OHDA-induced death in SH-SY5Y cells. J Neurochem 2004; 89: 124–133.
Motoyama N, Wang F, Roth KA, Sawa H, Nakayama K, Nakayama K et al. Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science 1995; 267: 1506–1510.
Parsadanian AS, Cheng Y, Keller-Peck CR, Holtzman DM, Snider WD . Bcl-xL is an antiapoptotic regulator for postnatal CNS neurons. J Neurosci 1998; 18: 1009–1019.
Li C, Fox CJ, Master SR, Bindokas VP, Chodosh LA, Thompson CB . Bcl-X(L) affects Ca(2+) homeostasis by altering expression of inositol 1,4,5-trisphosphate receptors. Proc Natl Acad Sci USA 2002; 9: 9830–9835.
Jonas EA, Hoit D, Hickman JA, Brandt TA, Polster BM, Fannjiang Y et al. Modulation of synaptic transmission by the BcL-2 family protein BCL-xL. J Neurosci 2003; 23: 8423–8431.
Zinkel S, Gross A, Yang E . Bcl2 family in DNA damage and cell cycle control. Cell Death Differ 2006; 13: 1351–1359.
Limana F, Urbanek K, Chimenti S, Quaini F, Leri A, Kajstura J et al. Bcl-2 overexpression promotes myocyte proliferation. Proc Natl Acad Sci USA 2002; 9: 6257–6262.
Sommer L, Rao M . Neural stem cells and regulation of cell number. Prog Neurobiol 2002; 66: 1–18.
Ostenfeld T, Svendsen CN . Requirement for neurogenesis to proceed through the division of neuronal progenitors following differentiation of epidermal growth factor and fibroblast growth factor-2-responsive human neural stem cells. Stem Cells 2004; 22: 798–811.
Martinez-Serrano A, Rubio FJ, Navarro B, Bueno C, Villa A . Human neural stem and progenitor cells: in vitro and in vivo properties, and potential for gene therapy and cell replacement in the CNS. Curr Gene Ther 2001; 1: 279–299.
Ourednik V, Ourednik J, Flax JD, Zawada WM, Hutt C, Yang C et al. Segregation of human neural stem cells in the developing primate forebrain. Science 2001; 293: 1820–1824.
Tabar V, Panagiotakos G, Greenberg ED, Chan BK, Sadelain M, Gutin PH et al. Migration and differentiation of neural precursors derived from human embryonic stem cells in the rat brain. Nat Biotechnol 2005; 23: 601–606.
Kee N, Sivalingam S, Boonstra R, Wojtowicz JM . The utility of Ki-67 and BrdU as proliferative markers of adult neurogenesis. J Neurosci Methods 2002; 115: 97–105.
Villa A, Snyder EY, Vescovi A, Martinez-Serrano A . Establishment and properties of a growth factor-dependent, perpetual neural stem cell line from the human CNS. Exp Neurol 2000; 161: 67–84.
Villa A, Navarro-Galve B, Bueno C, Franco S, Blasco MA, Martinez-Serrano A . Long-term molecular and cellular stability of human neural stem cell lines. Exp Cell Res 2004; 294: 559–570.
Rubio FJ, Bueno C, Villa A, Navarro B, Martinez-Serrano A . Genetically perpetuated human neural stem cells engraft and differentiate into the adult mammalian brain. Mol Cell Neurosci 2000; 16: 1–13.
Navarro-Galve B, Villa A, Bueno C, Thompson L, Johansen J, Martinez-Serrano A . Gene marking of human neural stem/precursor cells using green fluorescent proteins. J Gene Med 2005; 7: 18–29.
Lindsten T, Golden JA, Zong WX, Minarcik J, Harris MH, Thompson CB . The proapoptotic activities of Bax and Bak limit the size of the neural stem cell pool. J Neurosci 2003; 23: 11112–11119.
Nieto M, Schuurmans C, Britz O, Guillemot F . Neural bHLH genes control the neuronal versus glial fate decision in cortical progenitors. Neuron 2001; 29: 401–413.
Sun Y, Nadal-Vicens M, Misono S, Lin MZ, Zubiaga A, Hua X et al. Neurogenin promotes neurogenesis and inhibits glial differentiation by independent mechanisms. Cell 2001; 104: 365–376.
Horton S, Meredith A, Richardson JA, Johnson JE . Correct coordination of neuronal differentiation events in ventral forebrain requires the bHLH factor MASH1. Mol Cell Neurosci 1999; 14: 355–369.
Collier TJ, Sortwell CE, Daley BF . Diminished viability, growth, and behavioral efficacy of fetal dopamine neuron grafts in aging rats with long-term dopamine depletion: an argument for neurotrophic supplementation. J Neurosci 1999; 19: 5563–5573.
Peterson DA, Gnatenco C, Peterson LD . The aged brain exhibits impaired capacity to support neurogenesis. Exp Neurol 2003; 181: 102–103.
Liste I, Navarro B, Johansen J, Bueno C, Villa A, Johansen TE et al. Low-level tyrosine hydroxylase (TH) expression allows for the generation of stable TH+ cell lines of human neural stem cells. Hum Gene Ther 2004; 15: 13–20.
Tejero-Diez P, Rodriguez-Sanchez P, Martin-Cofreces NB, Diez-Guerra FJ . bFGF stimulates GAP-43 phosphorylation at ser41 and modifies its intracellular localization in cultured hippocampal neurons. Mol Cell Neurosci 2000; 16: 766–780.
Tamm C, Robertson JD, Sleeper E, Enoksson M, Emgard M, Orrenius S et al. Differential regulation of the mitochondrial and death receptor pathways in neural stem cells. Eur J Neurosci 2004; 19: 2613–2621.
Kanzawa T, Iwado E, Auki H, Iwamaru A, Hollingsworth EF, Sawaya R et al. Ionizing radiation induces apoptosis and inhibits neuronal differentiation in rat neural stem cells via c-Jun NH2-terminal kinase (JNK) pathway. Oncogene 2006; 25: 3638–3648.
Acknowledgements
This work was supported by grants from the European Union (QLK3-CT-2001–02120), Spanish Ministry of Science and Technology (MCYT – SAF2001-0841 and SAF2004-03405) and Comunidad Autonoma de Madrid (GR/SAL/0115/2004). The Institutional grant from Foundation Ramón Areces to the Center of Molecular Biology Severo Ochoa (CBMSO) is also gratefully acknowledged. We thank Dr. B Juliusson (Lund University Hospital) for providing human neurospheres for control experiments, and Dr. P Kusk (NsGene A/S, Denmark) for retroviral vectors. IL was supported by QLK3-CT-2001–02120 and the Comunidad Autónoma de Madrid. EGG and C Bueno are recipients of fellowships from the Spanish Ministry of Education. The excellent technical assistance of Bárbara B Sese, Inmaculada Ocaña, and Juliana Sánchez is also gratefully acknowledged.
Author information
Authors and Affiliations
Corresponding author
Additional information
Edited by G Cossu
Supplementary Information accompanies the paper on Cell Death and Differentiation website (http://www.nature.com/cdd)
Rights and permissions
About this article
Cite this article
Liste, I., García-García, E., Bueno, C. et al. Bcl-XL modulates the differentiation of immortalized human neural stem cells. Cell Death Differ 14, 1880–1892 (2007). https://doi.org/10.1038/sj.cdd.4402205
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cdd.4402205
Keywords
This article is cited by
-
Proteomics analysis of prefrontal cortex of Alzheimer’s disease patients revealed dysregulated proteins in the disease and novel proteins associated with amyloid-β pathology
Cellular and Molecular Life Sciences (2023)
-
Neuronal and Glial Differentiation of Human Neural Stem Cells Is Regulated by Amyloid Precursor Protein (APP) Levels
Molecular Neurobiology (2019)
-
Aβ42 Peptide Promotes Proliferation and Gliogenesis in Human Neural Stem Cells
Molecular Neurobiology (2019)
-
Overexpression of Bcl-2 promotes survival and differentiation of neuroepithelial stem cells after transplantation into rat aganglionic colon
Stem Cell Research & Therapy (2013)
-
Progress in Stem Cell Therapy for Major Human Neurological Disorders
Stem Cell Reviews and Reports (2013)